KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II Study of Novel Radiosensitizer for Cancer Radiotherapy
Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US. Currently ongoing Pivotal Phase II Study focuses on application of Kortuc radiosensitizer to locally advanced/recurrent breast cancer patients undergoing RT.
Comments from KORTUC
Comments from AXA Japan
About KORTUC Inc.
About AXA Japan
About AXA Group
*1 Clinical sites for Pivotal Phase II study
WiFi6: Securing the Remote Future
Who Benefits from Network Slicing?
Presentation Details TBA